

# Index

## A

- Acetylcholine (ACh), 29
- Activin/nodal (TGF $\beta$ ) pathway, 9
- Acute kidney injury (AKI), 201
- Adipogenicity, 131, 132
- Adipokines, 120
- Adipose derived adult stem cells (ADASs), 121
- Adipose derived stem cells (ADSCs)
  - AT, 121–126
    - bone marrow-derived MSCs, 121
    - characteristics, 128
    - MSC immunological markers, 122
    - SVF, 121–126, 128
- Adipose-derived SVF cells, 122
- Adipose memory, 131
- Adipose mesenchymal stem cells (AdMSCs), 121
- Adipose stem cells (ASCs)
  - ADASs, 121 (*see also* Adipose derived stem cells (ADSCs))
  - adipose tissue stroma, 121
  - antiadipogenic, 124
  - biomaterials, 134–137
  - BMP-4, 125
  - BMSCs, 121
  - culture conditions, 137–139
  - depots, 126–127
  - donors, 129–134
  - embryonic origin, 121
  - immunomodulatory properties, 122
  - media and supplements, 137–139
  - microenvironments, 126
  - pericytes, 126
  - procedures, 128
  - S-ASCs, 124
  - spindle shaped cells, 122
  - stemness, 124, 139–142
  - V-ASCs, 124
- Adipose stromal cells (ASCs), 121
- Adipose tissue (AT), 99, 168
  - BAT, 123
  - beige adipose tissue, 124
  - energetic homeostasis, 122
  - immunomodulators, 121
  - insulin resistance, 123
  - marrow adipose tissue (MAT), 124
  - pre-peritoneal, 131
  - single donor, 121
  - stem cells, 131
  - stroma, 121
  - SWAT, 123–125
  - VWAT, 123–125
  - WAT, 123, 124
- Adult carotid bodies, *see* Carotid bodies (CB)
- Adult germinal niches, 20
- Adult rat kidneys, 199
- Adult sarcomas, 96
- Adult stem cells (ASCs), 68, 156–157
- Age of donors, 132–134
- Aldefluor-positive cells, 105
- Allogeneic human serum (alloHS), 138
- $\alpha$ -Minimum essential medium (A-MEM), 134
- Angiogenesis, 22, 24, 30, 31
- Antiadipogenic, 124
- ATP, 29

## B

- Barrett's esophagus
  - bone marrow cells, 59
  - clinical challenges, 56

- Barrett's esophagus (*cont.*)
- clonal analysis, 66
  - description, 57
  - and dysplasia, 65
  - and EAC, 57, 64, 65
  - epithelium, 67
  - ESMG distribution, 58
  - existence, stem cells, 65
  - extensive analyses, 66
  - gastric intestinal metaplasia, 56
  - in vitro and in vivo, 67
  - migration, gastric cardiac epithelium, 58
  - mucosa, 64
  - ontogeny, 57
  - origin of, 57
  - p63 expression, 58
  - RECs, at squamocolumnar junction, 60–61
  - standard-of-care, 67
  - and stomach, 66
  - transcommitment, 59, 60
- Barrett's mucosa, 64
- Basic fibroblast growth factor (FGFb), 137
- Beige adipose tissue, 124
- Biomaterials
- ASCs
    - A-MEM, 134
    - CFUs, 135
    - characteristics, 135
    - DC, 136
    - design and development, 135
    - differentiation markers, 134
    - ECMs, 135–137
    - flow cytometry, 135
    - mechanical force transduction, 136
    - myogenic, 134
    - proliferation and differentiation, 134
    - StemPro, 134
    - 3D framework, 135
    - tridimensional natural-alike scaffolds, 135
    - 2D culture, 135
  - regenerative biological processes, 212
  - renal progenitor cells
    - alginate and chitosan, 211
    - ARPCs, 208, 211
    - electrospun nanofibers, 211
    - INHB-A, 211
    - micropatterning techniques, 207
    - nanomedicine, 203–204
    - nanotechnology, 203–204
    - podocyte markers, 211
    - polymer nanofibers, 211, 212
    - regulation of cellular functions, 204–207
    - tissue-culture polystyrene, 207
- Biomedical applications, 206
- Bio-printing
- 3D nanotechnologies, 159–161
- BM stem cells (BMSCs), 157
- Bmi-1, 197
- BMP-4, 125
- Body mass index (BMI), 129–131
- Bone marrow clonal MSC (BM-cMSC), 157
- Bone marrow-derived MSCs (BM-MSCs), 99, 102, 104, 105, 121, 167
- Bone morphogenetic proteins (BMP), 111
- Bone sarcomas, 96
- Bowman capsule, 200, 201
- Bromodeoxyuridine, 199, 200
- Brown adipose tissue (BAT), 123
- C**
- Cancer precursor, 56, 57, 59, 64
- Cancer prevention, 56–58, 60, 61, 67
- Carcinoma-associated fibroblasts (CAFs), 98
- Carotid bodies (CB)
- in blood PO<sub>2</sub>, 21
  - chemical stimuli, 21
  - germinal niche and tumorigenesis, 34
  - hypertrophy, 34
  - hypoxic stimulus, 24
  - malformation, 34
  - multipotent and restricted progenitor cells, 34
  - multipotent neural crest-derived stem cells, 22
  - nestin+ proliferative stem cells, 24
  - neural parenchyma, 21
  - neuroblast proliferation, to hypoxia, 28–29
  - neuroblasts (*see* CB neuroblasts (CBNBs))
  - neuronal glomeruli, 22
  - niche, 24
  - paragangliomas, 34
  - parenchyma, 24
  - pathophysiology, 33
  - physiological adaptation, 21, 22
  - proliferative potential, 34
  - remarkable oxygen detector in mammals, 34
  - resection and denervation, 33
  - type A glomus cells, 25
- CB neuroblasts (CBNBs)
- cellular origin, 25, 26
  - description, 25
  - HNK-1 expression, 25
  - marker expression, 26–27
  - maturation, to hypoxia, 29
  - mature hypoxia-responsive machinery, 25
  - proliferation, 28–29

CB stem cells (CBSCs), 24  
   angiogenic process, 30  
   cell fate mapping approach, 30  
   cell therapy, 34  
   ET-1 role, 30  
   GFAP+ CBSCs, 22  
   lineage progression, 29, 33  
   mesectodermal-restricted progenitors,  
     31–33  
   migration, 24  
   neurosphere-forming assays in vitro, 22  
 CD10, 31, 32  
 CD133<sup>+</sup>/CD24<sup>+</sup> cells, 197, 200  
 CD24, 197  
 CD31, 31, 32  
 CD34, 31, 32  
 Cell adhesion, 207  
 Cell-based therapies, 120, 133  
 Cell-matrix interaction, 205  
 Cell population, 133  
 Cell-repellent plate, 159  
 Cell-to-cell heterogeneity, 72  
 Cellular deregulation, 129  
 Cellular functions  
   biomaterial roles, 204–207  
 Chemokine receptor expression, 133  
 Chondrosarcoma, 96, 101–103  
 Cisplatin (CisPt), 202  
 Clonogenic neoblasts (c-neoblasts), 45, 46  
 Clonogenicity, 101, 108  
 Colonization, 59  
 Colony-forming units (CFUs), 135  
 Comma-shaped bodies, 197  
 Committed progeny, 45, 51  
 Comparative genome hybridization (CGH)  
   microarray, 87  
 Congenital central hypoventilation syndrome  
   (CCHS), 34  
 Copy number variations (CNVs), 78, 79  
 Culture, 137  
 Cytokines, 202  
 Cytoplasmic stress, 130  
 Cytotoxicity assays, 159

## D

Deep adipose tissue, 123  
 Denatured type I collagen (DC), 136  
 Diabetic nephropathy, 199  
 Differentially expressed genes (DEGs), 140  
 Differentiation  
   dopaminergic, 31  
   into TH<sup>+</sup> glomus cells, 26  
   mesectodermal-restricted progenitors, 31

  neuronal, 31  
   and proliferation, 20  
 DNA methylation, 79  
 DNA methylome analysis, 77  
 Donors  
   age, 132–134  
   BMI, 129–131  
   cell characteristics, 129  
   health status, 129  
   methylation patterns, 129  
   proliferation and differentiation, 129  
 Dopaminergic neuronal cells, 28, 34  
 Double chamber system, 157  
 Dry mouth, 152  
 Dulbecco's modified Eagle's medium  
   (DMEM), 134, 136, 137

## E

Egenerative medicine, 157  
 Electrospun nanofibers, 211  
 Embryonic development  
   cell fate transition, 185  
   dynamic alteration, 187  
   functional heterogeneity, 187, 188  
   GVBD, 186  
   mitochondrial accumulation, 187  
   mitochondrial spatial remodeling, 185–186  
   transverse relocation, 186  
 Embryonic stem cells (ESCs), 120, 180  
   blastocysts, 7  
   human, 10  
   and iPSCs, 75  
   mouse, 13  
   NT-ESCs, 77  
   time-lapse imaging, 80  
   in tissue regeneration, 121  
   transcription factors, 7  
 Endoplasmic reticulum (ER), 181  
 Endothelium, 98  
 Epiblast stem cells (EpiSCs)  
   brachyury/T, 7  
   characterization, 7  
   DNA methylation, 13  
   dynamic equilibrium, 9  
   embryo, 11  
   and ESCs, 6  
   gastrulation, 11  
   growth factors, 9  
   mesoderm/endoderm differentiation, 13  
   mouse pluripotent cells, 6  
   onset of gastrulation, 11  
   pluripotency, 5  
   proliferation, 10

Epiblast stem cells (EpiSCs) (*cont.*)  
 properties, 12  
 signalling pathways, 9, 10  
 Sox1, 8  
 T expression, 8  
 transcription factors, 7  
 Epidermal growth factor (EGF), 137  
 Epigenetic memory, 77  
 Epithelial cells, 152, 153, 156, 159, 160, 196  
 Esophageal adenocarcinoma (EAC)  
 Barrett's esophagus, 56  
 Cdx2 expression, 59  
 incidence, 64, 68  
 intestinal metaplasia, 56  
 mutations, 66  
 premalignant stages, 57  
 prevalence, 56  
 risk of, 57  
 statistic, 57  
 therapeutic approach, 65  
 Esophageal submucosal glands (ESMGs), 58  
 Ewing sarcoma, 104, 105, 108, 109  
 Exocrine glands, 161  
 Extracellular matrix (ECM), 135–137, 158,  
 204, 205

## F

Fate lineage tracking, 2  
 Fetal bovine serum (FBS), 138  
 Fetal stem cells (FSC), 120  
 Fibroblast-adipocyte precursor (FAP), 99  
 Fibroblast growth factor 2 (FGF2), 132  
 Fibroblast growth factor receptor 2b  
 (FGFR2b) signaling, 155  
 Fibroblastic growth factor (FGF)-Sox2  
 axis, 111  
 Fibrosarcoma, 96, 102, 104  
 Flatworms, *see* Planarian  
 Flow cytometry, 135  
 Fluorescence-activated cell sorting (FACS),  
 41, 47, 50  
 FUS-CHOP oncoprotein, 104, 105

## G

Gastric intestinal metaplasia, 56  
 Gene expression  
 analysis, 139  
 in ASCs, 125, 140  
 and cell biological behavior, 138  
 patterns, 138  
 post-induction, 141  
 profiles, 124

senescence markers, 132  
 signatures, 124  
 subcutaneous and gluteal depots, 125  
 Genetic and epigenetic plasticity  
 sarcoma stem cells, 108–110  
 Genome-wide transcriptome, 77  
 Germinal niche  
 adult, 20  
 niche functioning, 20  
 in PNS, 21  
 and tumorigenesis, 34  
 Germinal vesicle breakdown (GVBD), 186  
 Glomerular cells, 196, 200, 211  
 Glomerulosclerosis, 199

## H

Hair follicle-derived MSC, 157  
 Hematopoietic stem cells (HSC), 121  
 Heterogeneity  
 ADSC *Adipose derived stem cells*  
 (ADSCs)  
 EpiSCs (*see* Epiblast stem cells (EpiSCs))  
 MSCs  
 cell proliferation, 168  
 cell surface markers (*see* Surface  
 markers)  
 culture condition, 173  
 individual donors, 166, 167  
 tissue sources (*see* Tissue sources)  
 Human adipose-derived mesenchymal stem  
 cells (hAdMSCs), 157  
 Human adipose-derived stem cells  
 (hADSC), 140  
 Human embryonic stem cells (hESCs), 73, 75,  
 76, 79  
 Human induced pluripotent stem cells  
 (hiPSCs), 73, 75, 78, 79  
 Human pluripotent stem cells (hPSCs)  
 conventional, 76  
 culture conditions, effect of, 76  
 culture media, 76  
 genetic instability and heterogeneity, 82  
 noninvasive computation image analysis, 84  
 quality control  
 cell morphology, 86  
 CGH microarray/SNP analysis, 87  
 differentiation potential, 88  
 genotyping techniques, 87  
 growth rate, 86  
 in vitro culture, 86  
 marker genes and antigen expression,  
 characterization, 87  
 research, 86

- two-dimensional imaging cytometry, 85
  - types, 75
  - validation, standardization and regulation, 73
  - Human umbilical cord perivascular cells (HUCPVCs), 168
  - Hyaluronic acid (HA) hydrogels, 158
  - Hypofunction, 152, 153
  - Hypoxia-inducible factors (HIFs), 28
- I**
- Immunohistochemical analysis, 159–160
  - Immunomodulatory capacity, 138
  - In vitro sarcoma progression models, 98, 100, 102, 103
  - Induced pluripotent stem cells (iPSCs), 180
    - de novo mutations, 75
    - ESCs, 72
    - genetic changes, 75
    - hPSCs, 73
    - mutations, 74
    - NLRP3-mutant and nonmutant, 74
    - and NT-ESCs, 76, 77
    - pancreatic beta-cell-derived iPSCs, 77
  - Inflammatory chemokines, 202
  - INH-B-A-loaded Polysaccharides Synthetic Vesicles (INH-B-A-PSSV), 211
  - Insulin growth factor (IGF), 137
  - Insulin like growth factor (ILF), 128
  - International Society for Cellular Therapy (ISCT), 128, 166
  - Intestinal metaplasia, 56, 57, 61, 65
  - Ischemia-reperfusion model, 199
  - Issue engineering
    - 3D strategies, 157–159
- K**
- Kidney regeneration, 196–199
  - KIT-expressing (KIT+) progenitors, 153, 155
- L**
- Leiomyosarcoma, 96, 101, 104, 110
  - Leptin transcript levels, 131
  - Liposarcoma, 96, 98, 101–104, 109, 110
  - Low-affinity nerve growth factor receptor (LNGFR), 170
- M**
- Magnetic bio-printing systems, 159–161
  - Melanoma cell adhesion molecule (MCAM), 171
  - Mesectoderm-restricted progenitors, 26
    - CBSCs, in neurogenesis, 30
    - ET-1 role, 30
    - and vascular potency, 30
    - within adult CB, 31–33
  - Mesenchymal
    - AdMSCs, 121
    - and endothelial progenitor cells, 122
    - lineages, 128, 142
    - MSCs, 121, 123, 137
    - multipotency, 127
    - tissues, 120
  - Mesenchymal stem cells (MSCs), 166
    - biological properties, 166
    - BM, 99
    - bone marrow and white adipose tissue, 98
    - CAFs, 98
    - cellular markers, 166
    - endothelium, 98
    - FAP, 99
    - features, 166
    - fibroblasts, 98
    - heterogeneity, 167 (*see also* Heterogeneity)
    - identification, 128
    - immune modulation, 166
    - immunological markers, 122
    - immunomodulatory ability, 166
    - in vitro, 98
    - ISCT criteria, 166
    - mechano-sensing influence, 136
    - molecular biology, 99–101
    - pluripotency, 120
    - regenerative properties, 166
    - sarcomagenesis, 102–105
    - stemness and differentiation, 99–101
    - types, 101
  - Metanephric mesenchyme, 197
  - Metaplasia markers, 60
  - Micro RNAs (miRNAs), 141
  - Microarray analysis, 141
  - Micro patterning techniques, 207
  - Microvesicles, 212
  - Mitochondria
    - alterations in distribution, 187
    - ATP production, 181
    - biogenesis and selective degradation, 181
    - configurational changes, 181
    - double-membraned organelles, 180
    - ER, 181
    - morphological features, 181
    - mtDNA and perinuclear distribution, 183
    - oxidative capacity, 184–185
    - primed stem cells, 184
    - respiratory activity, 184

- Mitochondria (*cont.*)  
 respiratory complexes, 180  
 ROS, 183  
 structure and function, 180, 181
- Mitochondrial fusion, 188, 189
- Mitochondrial heterogeneity  
 distributional, 182  
 functional, 183  
 fusion and fission, 188, 189  
 metabolism, 185  
 structural, 181, 182
- Molecular biology techniques, 46
- Mouse epiblast stem cells  
 (mEpiSCs/mESCs), 76
- Multipotency, 20, 31
- Muscle derived stem cells, 133
- Myoepithelial cells, 158
- N**
- Naïve neoblast model, 45
- Nanog, 80, 81
- Nanog-GFP, 82
- Nanomedicine, 203–207
- Neoblast 2.0, 50
- Neoblasts  
 behavioral parameter, 41  
 description, 39  
 discovery, 39, 51  
 distribution, in *S. mediterranea* and *D. japonica*, 41, 42  
 genes, 41  
 morphology, 39, 40, 42  
 naïve vs. specialized neoblast model, 45–46  
 parenchyma, 41  
 planarian regeneration, 42–45  
 proliferative cells, 41  
 radiosensitivity, 43  
 requirements, 43  
 single cell RNA sequencing  
 cells sharing gene expression, 49  
 clustering, 49  
 lineage progenitors, 50  
 punctual analysis, 47  
 $\sigma$ -class and  $\zeta$ -class, 48, 49  
 super-resolution microscopy, 50  
 tetraspanin, 50  
 zeta-class ( $\zeta$ -class), 47  
 single cell transcriptional profiling, 48
- “Neoblast-free” planarians, 41
- Neochromosomes, 98, 101, 109
- Neogenesis, 199
- Nephron, 196, 197, 199, 200
- Neural crest  
 adult germinal niches, 20  
 CB, 21  
 CD34, 31  
 during development, 25  
 HNK-1, 25  
 multipotent neural crest-derived stem cells, 22
- Neural crest-derived stem cells (NCSCs), 20, 30
- Neuroblasts, 20, 25  
*See also* CB neuroblasts (CBNBs)
- Neurogenesis, 20, 22, 24, 28, 30
- Neurons, 196
- Nodal signalling, 12
- O**
- Obese adipose tissue, 130
- Oct-4, 197
- Osteosarcoma, 96, 101, 104, 110–112
- Oxidative species, 129
- Oxidative stress, 133
- P**
- p53, 99–101, 104, 109
- p63ko mouse model, 60
- Paracrine, 202
- Pax2, 197
- Pericytes, 126
- Peripheral nervous system (PNS), 20–22
- Perivascular, 126
- phmSG cells, 156
- Piwi, 43, 50
- Placenta (P-MSCs), 169
- Planarian  
 “germline multipotency program”, 40  
 intestine, 48  
 mouth, 41  
 “neoblast-free”, 41  
 neoblasts (*see* Neoblasts)  
 regeneration, 42–45  
 research, 50
- Platelet derived growth factor (PDGF), 128, 137
- Platyhelminthes, *see* Planarian
- Pluripotent stem cells (PSCs)  
 clonal selection, existing somatic mutations, 74  
 de novo mutations, 75  
 donor variation, genetic variability, 73, 74  
 early embryonic development, 72  
 epigenetic heterogeneity, cell lines, 79

- epigenetic memory, 77
  - factors influencing heterogeneity, 78
  - genetic heterogeneity, cell lines, 78, 79
  - imaging methods, heterogeneity detection
    - cell growth, 83, 84
    - flow cytometry, 85
    - machine learning, 83
    - merged image, immunostaining, 85
    - phase contrast images, 83, 84
    - time-lapse live-cell phase-contrast images, 83
  - properties, 72
  - reprogramming methods, 77
  - temporal fluctuation
    - maintaining pluripotency, 80–81
    - Nanog, 80
    - PSC-related genes, 80
  - Podocytes, 196, 199, 201
  - Poly(lactic)-co-glycolic acid (PLGA), 158, 159
  - Polycarbonate membrane, 211
  - Polymer nanofibers, 211, 212
  - Poly-*N*-isopropyl-acrylamide system (PNIPAM), 211
  - Polysaccharides, 206
  - pRb, 99, 100, 104
  - Primitive vesicles, 197
  - Progenitor cells
    - healing and natural gland regeneration, 152
    - salispheres, 152
    - SG, 158
    - and stem cells
      - c-KIT+ cells, 155
      - FGFR2b signaling, 155
      - human minor SG cells, 156
      - hypofunction, 153
      - in vitro salisphere cultures, 153
      - in vivo transplantation, 155
      - K5+, 156
      - karyotypic changes, 155
      - KIT+ progenitors, 153, 155
      - major SG transplants, 156
      - markers, 156
      - methodologies, cryopreservation and biobanking, 155
      - phmSG cells, 156
      - salisphere-based cultures, 155
  - Proliferation, 20, 22, 28–30, 33, 34
  - Prolyl-hydroxylases (PHDs), 28
  - Proteoglycans, 204
- R**
- Radiation-induced xerostomia, 152
  - Radiation therapy (RT), 152
  - Reactive oxygen species (ROS), 181, 183
  - Regeneration
    - and normal tissue homeostasis, 45
    - Piwi-1<sup>high</sup> cells, 50
    - planarian, 42–45
    - protonephridia, 46
  - Regenerative medicine, 161
  - Renal progenitor cells
    - biomaterials (*see* Biomaterials)
    - chronic treatment, 199
    - diabetic nephropathy, 199
    - gene expression, 202
    - in humans, 200–203
    - in rats and mice, 199–200
    - TLRs, 202
    - type 1 diabetes mellitus, 199
  - Renal proximal tubular epithelial cells (RPTECs), 211
  - Renal stem cells
    - adult renal progenitors (*see* Renal progenitor cells)
    - integrity and functionality, 196
    - regenerative capacity, 196–199
    - staminal markers, 197
  - Renal vesicle, 197
  - Residual embryonic cells (RECs)
    - in adult mice, 61
    - Barrett's esophagus, 61
    - discovery, 61
    - at squamocolumnar junction, E18 embryos, 61
  - Rhabdomyosarcoma, 96, 101, 102
- S**
- Salivary glands (SG)
    - advantages and limitations, 152–154
    - ASCs, 156–157
    - biotechnology strategies, 152
    - dry mouth, 152
    - epithelial cells, 152
    - hypofunction, 152
    - issue engineering, 157–159
    - radiation field, 152
    - regeneration, 152
    - RT, 152
    - stem and progenitor cells, 153–156
    - 3D bio-printed magnetic nanotechnologies, 159–161
    - xerostomia, 152
  - Sarcoma stem cells
    - genetic and epigenetic plasticity, 108–110
    - marker-free approach, 105
    - microenvironment, 110–111

- Sarcoma stem cells (*cont.*)  
 MSCs (*see* Mesenchymal stem cells (MSCs))  
 stem cell markers, 105–108  
 Wnt inhibitor Dickkopf-1, 105
- Sarcomagenesis, 102–105
- Sarcomas  
 classification, 96  
 pediatric, 96  
 structural chromosomal, 96–98
- Senescence, 132
- Serum-free culture medium, 138
- Serum-free media/xeno-free FDA-approved culture medium (SFM/XF), 138, 139
- Serum supplementation, 134, 137
- Side population (SP), 105
- Sigma ( $\sigma$ )-neoblasts, 49
- Signalling pathways  
 activin/nodal (TGF $\beta$ ), 9  
 FGF, 10  
 WNT, 10
- Single cell RNA sequencing, 2
- Single-nucleotide polymorphisms (SNPs), 75, 87
- SIRT-1, 99–102
- Six2 gene, 197
- Sjögren's syndrome, 152
- Skeletal stem cells, 99
- Slow cycling cells, 199
- Soft tissue sarcomas, 96
- Sox-2, 99, 101, 102, 109
- Sox-9, 99, 100
- Squamous metaplasia, 59
- SS18-SSX, 108
- S-shaped bodies, 197, 198
- Staminal markers, 197
- Stem cell cloning, 61
- Stem cells  
 classifications, 120, 180  
 embryonic *vs.* non-embryonic, 180  
 functioning, 2  
 heterogeneity, 2  
 mitochondria, 180  
 planarian (*see* Planarian stem cells) and progenitor, 153–156  
 properties, 128  
 types, 180
- Stem cell therapy, 167, 174
- Stemness, 124, 136–142
- StemPro, 134
- Stromal cells, 111
- Stromal vascular fraction (SVF), 121–126, 130  
 ASCs, 131, 133  
 and AT, 122  
 cell composition, 127  
 cell yield and proliferation capacity, 132  
 characteristics, 127  
 collagen matrix, 122  
 definition, 122  
 healing factors, 127  
 liposuction, 122  
 MSC markers, 122  
 plastic express, 128  
 proportion profiles, 127  
 stem cells, 128  
 subpopulations, 127  
 SWAT, 124, 131  
 tissues and organs, 122
- Subcutaneous white adipose tissue (SWAT), 123–125
- Subpopulations, 169, 172, 173
- Sudden infant death syndrome (SIDS), 34
- Superoxide dismutase (SOD), 133
- Surface markers, 126  
 CD106, 171, 172  
 CD146, 171  
 CD271, 170, 171  
 nestin, 172, 173  
 Stro-1, 170
- Surface protein markers, 200
- Synovial sarcoma, 105, 108, 109
- Synthetic materials, 206, 207
- T**
- Tetraspanin, 50
- TGF- $\beta$  superfamily, 137
- Three-dimensional (3D) tissue engineering strategies, 157–159
- 3D reconstitution imaging technology, 181
- 3D spheroids, 158
- Tissue-culture polystyrene, 207
- Tissue engineering, 207
- Tissue sources  
 ASCs *vs.* MSCs population, 168, 169  
 CL-MSCs, 169  
 HUCPVCs *vs.* BMSCs, 168  
 immunomodulatory ability, 169  
 P-MSCs, 169  
 pro-angiogenic activities *vs.* CD106-MSCs, 169  
 UC-MSCs *vs.* BM-MSC, 168  
 WJ-MSC *vs.* AT-MSC, 168
- Tissue-specific/somatic stem cells, 20
- Toll-like receptors (TLRs), 202
- Transcriptome, 133
- Transepithelial electrical resistance (TER), 156
- Transforming growth factor  $\beta$  (TGF- $\beta$ ), 111



- Tridimensional natural-alike scaffolds, 135  
Tubular cells, 196, 197, 200–202, 211  
Tubules, 201  
Tumorigenicity, 101, 108  
Type 1 diabetes mellitus, 199
- U**  
Umbilical cord blood-mesenchymal stem cells (CB-MSCs), 169  
Umbilical cord lining-mesenchymal stem cells (CL-MSCs), 169  
Umbilical cords-mesenchymal stem cells (UC-MSCs), 167
- V**  
V-ASCs, 124  
Vascular cell adhesion protein 1/vascular cell adhesion molecule 1 (VCAM-1), 171  
Vascular cells, 22, 30  
Vascular endothelial growth factor (VEGF), 132, 137
- Visceral white adipose tissue (VWAT), 123–125
- W**  
Western blotting, 160  
Wharton's jelly (WJ), 168  
White adipose tissue (WAT), 123, 124  
WNT pathway, 10, 105, 111  
     $\beta$ -catenin pathway, 100  
    blastocysts, 12  
    inhibitors, 12  
Wolff's duct, 197
- X**  
Xeno-free (XF), 138  
Xerostomia, 152
- Z**  
Zeta ( $\zeta$ )-neoblasts, 49